Skip to main content
SpringerLink
Log in

Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235–242

    Article  CAS  Google Scholar 

  2. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    Article  CAS  Google Scholar 

  3. Herold M, Haas A, Srock S, Neser S, al-Ali KH, Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U, East German Study Group Hematology and Oncology Study (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986–1992

    Article  CAS  Google Scholar 

  4. Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, Kinoshita T, Naoe T (2007) Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 86:49–57

    Article  CAS  Google Scholar 

  5. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885–4893. https://doi.org/10.1182/blood-2008-08-175208

    Article  CAS  PubMed  Google Scholar 

  6. Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37:563–570. https://doi.org/10.1097/PAS.0b013e3182759008

    Article  PubMed  Google Scholar 

  7. Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, Naoe T (2009) Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of complex and not by DNA methylation. Biochem Biophys Res Commun 390:48–53. https://doi.org/10.1016/j.bbrc.2009.09.059

    Article  CAS  PubMed  Google Scholar 

  8. Rahme R, Benayoun E, Pautas C et al (2013) Treatment with 5-azacytidine upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Exp Hematol 41:505–507. https://doi.org/10.1016/j.exphem.2013.02.011

    Article  PubMed  Google Scholar 

  9. Tsutsumi Y, Ohigashi H, Ito S, Shiratori S, Teshima T (2016) 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report. J Med Case Rep 10:27. https://doi.org/10.1186/s13256-016-0809-7

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tomita A (2016) Genetic and epigenetic modulation of CD20 expression in B-cell malignancies: molecular mechanisms and significance to rituximab resistance. J Clin Exp Hematop 56:89–99

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Toyota Kosei Hospital, 500-1, Ibobara, Josui-cho, Toyota City, 470-0396, Japan

    Junji Hiraga, Naruko Suzuki, Yusuke Takagi & Yoshitoyo Kagami

  2. Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan

    Akihiro Tomita

  3. Department of Pathology, Toyota Kosei Hospital, Toyota, Japan

    Michihiko Narita

Authors
  1. Junji Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akihiro Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naruko Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yusuke Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michihiko Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitoyo Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junji Hiraga.

Ethics declarations

Informed consent

Written informed consent was obtained from the patient for publication when he was alive. This study was performed in conformity with the Declaration of Helsinki and was approved by our ethical committee.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiraga, J., Tomita, A., Suzuki, N. et al. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab. Ann Hematol 97, 2253–2255 (2018). https://doi.org/10.1007/s00277-018-3354-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3354-1

Search

Navigation